[go: up one dir, main page]

BRPI0409609A - mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia - Google Patents

mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia

Info

Publication number
BRPI0409609A
BRPI0409609A BRPI0409609-6A BRPI0409609A BRPI0409609A BR PI0409609 A BRPI0409609 A BR PI0409609A BR PI0409609 A BRPI0409609 A BR PI0409609A BR PI0409609 A BRPI0409609 A BR PI0409609A
Authority
BR
Brazil
Prior art keywords
treatment
hypercholesterolemia
cholesterol transport
reverse cholesterol
transport mediators
Prior art date
Application number
BRPI0409609-6A
Other languages
English (en)
Inventor
Jagadish C Sircar
Kashinatham Alisala
Igor Nikoulin
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BRPI0409609A publication Critical patent/BRPI0409609A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"MEDIADORES DO TRANSPORTE REVERSO DE COLESTEROL PARA O TRATAMENTO DA HIPERCOLESTEROLEMIA". A presente invenção proporciona composições adaptadas para estimular o transporte reverso de colesterol em mamíferos. As composições são adequadas para a transferência oral e úteis no tratamento e/ou prevenção da hipercolesterolemia, arteriosclerose e doenças cardiovasculares associadas.
BRPI0409609-6A 2003-04-22 2004-04-22 mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia BRPI0409609A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46466703P 2003-04-22 2003-04-22
PCT/US2004/012445 WO2004094471A2 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Publications (1)

Publication Number Publication Date
BRPI0409609A true BRPI0409609A (pt) 2006-04-18

Family

ID=33310929

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409609-6A BRPI0409609A (pt) 2003-04-22 2004-04-22 mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia

Country Status (18)

Country Link
US (1) US20060166891A1 (pt)
EP (1) EP1615954A2 (pt)
JP (1) JP2007534612A (pt)
KR (1) KR20050114283A (pt)
CN (1) CN1809590A (pt)
AR (1) AR044058A1 (pt)
AU (1) AU2004233333A1 (pt)
BR (1) BRPI0409609A (pt)
CA (1) CA2522758A1 (pt)
CL (1) CL2004000858A1 (pt)
IS (1) IS8072A (pt)
MX (1) MXJL05000046A (pt)
NO (1) NO20055474L (pt)
PE (1) PE20050136A1 (pt)
RU (1) RU2005135139A (pt)
TW (1) TW200503747A (pt)
UY (1) UY28282A1 (pt)
WO (1) WO2004094471A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511871A (pt) * 2004-06-09 2008-01-15 Avanir Pharmaceuticals moléculas pequenas para tratamento de hipercolesterolemia e doenças relacionadas
CA2568394A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
CA2568543A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
EP2234493A4 (en) * 2007-12-21 2011-05-25 Univ Cincinnati THERAPEUTIC USE OF CARBOXYLESTERLIPASE INHIBITORS
GB0918579D0 (en) * 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
WO2011079214A1 (en) * 2009-12-23 2011-06-30 Artery Therapeutics, Inc., Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
US20110288017A1 (en) * 2010-03-01 2011-11-24 Leslie Frost Apo-lipoprotein propeptide
WO2017208149A1 (en) 2016-05-31 2017-12-07 Institut De Cardiologie De Montreal A co-culture system and method for in vitro assessment of reverse cholesterol transport
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
WO2025024564A1 (en) * 2023-07-24 2025-01-30 The Board Of Regents Of The University Of Texas System Small molecules that prevent statin-induced accumulation of hmg coa reductase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE437153B (sv) * 1976-12-01 1985-02-11 Kabi Ab Specifika kromogena enzymsubstrat for serinproteaser
US4448715A (en) * 1981-11-02 1984-05-15 University Of Miami Tagged pyroglu-L-Phe-L-Arg derivatives, substrates and assays for kallikrein
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3781263T2 (de) * 1986-12-15 1993-04-08 Inst Nat Sante Rech Med Peptid-derivate und deren verwendung in der therapie.
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
AU8334298A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
AU1384302A (en) * 2000-11-10 2002-05-21 Proteopharma Aps Apolipoprotein analogues
EP1383922A4 (en) * 2001-04-10 2005-03-30 Agensys Inc NUCLEIC ACID AND ASSOCIATED PROTEIN SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER WITH THE LABEL 158P3D2

Also Published As

Publication number Publication date
AR044058A1 (es) 2005-08-24
WO2004094471A3 (en) 2005-06-16
CN1809590A (zh) 2006-07-26
KR20050114283A (ko) 2005-12-05
CA2522758A1 (en) 2004-11-04
US20060166891A1 (en) 2006-07-27
MXJL05000046A (es) 2005-12-22
AU2004233333A1 (en) 2004-11-04
PE20050136A1 (es) 2005-04-20
TW200503747A (en) 2005-02-01
JP2007534612A (ja) 2007-11-29
NO20055474L (no) 2006-01-23
UY28282A1 (es) 2004-11-30
RU2005135139A (ru) 2007-05-27
WO2004094471A2 (en) 2004-11-04
EP1615954A2 (en) 2006-01-18
NO20055474D0 (no) 2005-11-18
CL2004000858A1 (es) 2005-04-22
IS8072A (is) 2005-10-13

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
GEP20125565B (en) Lactam compounds and their pharmaceutical use
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
TW200602042A (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
PL374524A1 (en) Composition based on triethyl citrate for the treatment of bacterial infections of the skin
TW200504051A (en) Novel acridine derivatives and their use as medicaments
AU4568400A (en) Sphingomyelinase inhibitor
BR0108096A (pt) Método para manter ou melhorar a sìntese de mucinas
GB0012795D0 (en) Organic compounds
BRPI0511945A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
BRPI0511871A (pt) moléculas pequenas para tratamento de hipercolesterolemia e doenças relacionadas
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
HK1050203A1 (en) Novel fusidic acid derivatives.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.